Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 14/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20883081 | 0.76 | SMN1; SMN2 (0.59) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL23452840 | 0.75 | UCHL1 (0.40) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL17632008 | 0.75 | UCHL1 (0.44) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL17644063 | 0.75 | UCHL1 (0.44) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL22522971 | 0.75 | SMN1; SMN2 (0.45) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL17632005 | 0.74 | — | — | |
| SCHEMBL21845349 | 0.73 | CCNE1 (0.36) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20877327 | 0.70 | UCHL1 (0.45) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20877325 | 0.70 | UCHL1 (0.45) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20522416 | 0.68 | CCNE1 (0.48) | CDK2CCNE1CDK5CDK5R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | CDK2 2917/4885CDK9 1508/4885CCNE1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.